Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Hired experts support claims St. Jude heart devices can be hacked

Short-selling firm Muddy Waters said in a legal brief that outside cyber security experts it hired have validated its claim that St. Jude Medical Inc. cardiac implants are vulnerable to potentially life-threatening cyber attacks.

Read More »

FDA Slaps Partial Hold on Bay Area Firm Aduro Biotech’s Cancer Vaccine Trial

The U.S. FDA placed a partial hold on Berkeley, Calif.-based Aduro Biotech’s LADD trials.

Read More »

GSK files shingles vaccine for U.S. approval

GlaxoSmithKline has filed its shingles vaccine Shingrix for U.S. regulatory approval, bringing the potential $1 billion-a-year seller a step closer to market.

Read More »

Sanders urges Californians to approve drug price ballot measure

Former Democratic presidential candidate Bernie Sanders, in an opinion editorial published in the Los Angeles Times, urged Californians to approve a November ballot measure aimed at reining in pharmaceutical prices.

Read More »

Polio vaccine makers failing to make enough doses: WHO experts

Two companies making vaccines to help the world eradicate polio are failing to produce enough, so many countries should prepare to give lower doses to make stocks last, a group of experts has advised the World Health Organization.

Read More »

Rehab after heart attack tied to longer, not healthier life

Heart attack survivors who participate in cardiac rehabilitation programs may survive longer, but feel no healthier, than they would without this follow-up care, a U.S. study suggests.

Read More »

Indian doctor accused of crimes becomes president of World Medical Association

The World Medical Association (WMA), the top medical-ethics body, installed an Indian doctor facing corruption charges as its president despite controversy surrounding his appointment while legal cases are pending.

Read More »

One Fine Specimen: Where Biopharma Competitiveness Really Begins

Before there are new therapies to set a firm apart, there is a far more fundamental need that competitiveness will ultimately hinge on: high-quality, diversified, annotated human biospecimens.

Read More »

Merck’s Keytruda Wows in Bladder Cancer Trial

Merck & Co. ended a Phase III trial of Keytruda in advanced urothelial cancer because the immuno-oncology drug met its primary endpoint.

Read More »

Alkermes Depression Drug Aces Key Study

Alkermes’ experimental anti-depression drug ALKS-5461 significantly reduced symptoms in major depressive disorder patients not helped by standard treatments.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom